Allurion Technologies presented new clinical data on its flagship Allurion Balloon and AI-powered Virtual Care Suite, showcasing their combined impact on weight loss and body composition—both independently and alongside GLP-1 medications. Designed as a non-surgical weight loss solution, the Allurion Balloon is used in conjunction with the company’s digital health platform to track and optimize patient outcomes. The new findings highlight the potential of integrated digital and pharmacologic approaches in managing obesity more effectively.

The data demonstrate that patients using the Allurion system—with or without GLP-1 medications—experienced significant fat loss while preserving lean muscle mass, a key factor in long-term metabolic health. The addition of GLP-1s, such as semaglutide, showed incremental benefits when paired with the Allurion Virtual Care Suite, which offers AI-driven coaching, behavior tracking, and clinician oversight. This synergy helps individualize treatment pathways, offering tailored support that enhances adherence and accelerates results.

Allurion’s latest research reinforces the effectiveness of combining medical technology with digital tools and pharmacotherapy to achieve sustainable, comprehensive weight loss. As obesity care moves toward more personalized, multimodal approaches, Allurion is positioning itself at the forefront of innovation in metabolic health. These results could expand treatment accessibility and optimize long-term outcomes for millions struggling with obesity worldwide.

MedTech Spectrum's Summary

Allurion’s new data shows its Balloon and AI Virtual Care Suite promote significant fat loss with muscle preservation.

Combining the system with GLP-1s like semaglutide further improves weight loss outcomes.

The findings support a multimodal, tech-enabled approach to obesity care, advancing personalized and effective treatment options.